TORONTO, Dec. 6, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today
that it has established a collaboration with CNJ Holdings Inc., a
wholly-owned subsidiary of Cangene Corporation, for the identification
and development of therapeutic antibodies against proprietary disease
specific epitopes (DSEs) identified using Amorfix's ProMIS™ discovery
technology for the treatment of various oncology indications.
"This collaboration represents the ideal situation where two companies
come together with complementary expertise, resources and technology in
a united effort to identify and develop novel antibody therapeutics for
the treatment of cancer", said Dr. Robert Gundel, Amorfix President and
CEO. "Establishing partnerships and strategic alliances to accelerate
the discovery, development and commercialization of therapeutic
antibodies is part of our overall strategy to build our product
Amorfix's current therapeutic portfolio includes antibodies directed
against a number of misfolded protein targets for the treatment of a
variety of cancers including ovarian cancer, melanoma and leukemia.
This new collaboration with Cangene allows Amorfix continue to build
and expand its innovative product pipeline of cancer therapeutics.
"We are excited about this collaboration with Amorfix which brings new
energy to our R&D pipeline development efforts" said John Sedor,
Cangene's President and CEO. "This is an opportunity to leverage our
core competencies to accelerate the development of therapeutic
antibodies to novel targets in the oncology space" he added.
The terms of the collaboration were not disclosed.
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS™, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection™ and
AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a cerebrospinal fluid (CSF) screening test
for Alzheimer's disease (AD), and an ultrasensitive method for
detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue,
CSF and blood from animal models of AD. For more information about
Amorfix, visit www.amorfix.com.
About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is
one of the nation's oldest and largest biopharmaceutical companies. It
is focused on the development and commercialization of specialty
therapeutics. Cangene's products are sold worldwide and include
products that have been accepted into the U.S. Strategic National
Stockpile. Cangene has offices in three locations across North America.
It operates manufacturing facilities in Winnipeg, Manitoba and
Baltimore, Maryland (through its wholly owned subsidiary, Cangene
bioPharma, Inc.) where it produces its own products and undertakes
contract manufacturing for a number of customers. Cangene also operates
a plasma-collection facility in Winnipeg, Manitoba under the name
Cangene Plasma Resources. Its U.S. sales and marketing office is
located in Philadelphia, Pennsylvania. For more information about
Cangene, visit the Company's website at www.cangene.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
SOURCE: Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899